Sodium bicarbonate injection recalled after arsenic exceeded impurity specification
Exela 4.2% Sodium Bicarbonate Injection USP, 5 mEq/10 mL, lot 10004077, is recalled nationwide after out-of-specification results for arsenic in impurities testing.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Rubric level 3 covers risk-of-harm products where injury has not yet been reported; an injectable medicine with arsenic above its impurity specification is a potential harm and no injuries are reported.
Plain-English summary
4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL), for intravenous use only in 10 mL single dose vials, manufactured and distributed by Exela Pharma Sciences, LLC of Lenoir, North Carolina, NDC 51754-5012-1 for the vial and 51754-5012-4 for the carton, is being recalled. The affected product is lot 10004077 with an expiry of 02/28/2026, distributed nationwide.
The recall was issued because the product failed impurities and degradation specifications, with out-of-specification results for arsenic in the impurities tested. The FDA classified the action as Class II.
Hospitals and pharmacies holding this lot should quarantine it, stop using it, and follow the manufacturer's instructions for return or replacement.
The recalled product
- Product
- SODIUM BICARBONATE (SODIUM BICARBONATE)
- Brand
- SODIUM BICARBONATE
- Manufacturer
- Exela Pharma Sciences LLC
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 10004077
- Exp. 02/28/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · SODIUM BICARBONATE
- HighSodium bicarbonate injection vials recalled for lack of assurance of sterility
FDA (Drugs) · 2025-08-27
- HighSodium Bicarbonate Injection Recalled Due to Sterility Assurance Issue
FDA (Drugs) · 2025-04-02
- SevereFDA Recalls Sodium Bicarbonate Injection Due to Glass Particle Contamination
FDA (Drugs) · 2024-01-24
- SevereFDA Recalls Sodium Bicarbonate Injection for Silicone Particulate Contamination
FDA (Drugs) · 2023-11-29
- SevereFDA Recalls Sodium Bicarbonate Injection for Defective Vials
FDA (Drugs) · 2022-12-21
Same manufacturer · Exela Pharma Sciences LLC
See all →- SevereMidazolam Injectable Recalled for Silicone Particulate Matter Contamination
FDA (Drugs) · 2023-11-29
- SevereELCYS cysteine hydrochloride injection recalled for silicone contamination
FDA (Drugs) · 2023-11-29
- SevereFDA Recalls Sodium Bicarbonate Injection Vials for Glass Breakage Risk
FDA (Drugs) · 2022-12-21
- SevereSodium Bicarbonate Injection Recalled for Defective Vials and Glass Breakage
FDA (Drugs) · 2022-11-02
Same hazard · failed specification
See all →- ModerateSodium iodide capsule packs recalled after failing capsule specifications
FDA (Drugs) · 2026-04-01
- HighMeclizine hydrochloride 12.5 mg tablets recalled after failing tablet specifications
FDA (Drugs) · 2026-04-01
- HighIcosapent ethyl capsules recalled after active ingredient oxidized inside capsule
FDA (Drugs) · 2026-03-18
- ModerateAmphetamine extended-release capsules 10 mg recalled over failed degradation specifications
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 20 mg recalled over impurity and degradation results
FDA (Drugs) · 2025-10-01